Stock listing

VTGN Stock Price, News, Filings & Events — Vistagen Therapeutics, Inc.

Selected listing: VTGN · BMV · MXN · MX

This page tracks Vistagen Therapeutics, Inc.'s VTGN:BMV listing on BMV in MXN for MX, including stock price context, company news, filings, investor events, AI research briefs, and market updates for investors following VTGN:BMV. VTGN:BMV is the stock-level entry point for investors researching Vistagen Therapeutics, Inc., while company-level investor report content can remain shared across the same issuer's public listings. 6ix connects this selected listing to available company updates, filings, investor events, replay content, and AI research briefs so stock search leads to the relevant company context without making another exchange listing primary. Vistagen Therapeutics, Inc. is a public company traded under the ticker VTGN in the American market. The company has a market capitalization of approximately $9.4 million. Vistagen focuses on developing therapies for central nervous system disorders.

VTGN:BMVMXNMXUpdated July 31, 2026
Vistagen Therapeutics, Inc. logo
Ticker
VTGN:BMV
Asset type
Stock
Market cap
$9.9M
Sector
Health Technology
Industry
Biotechnology
Exchange
BMV
Currency
MXN

Vistagen Therapeutics, Inc. VTGN:BMV stock context

This page tracks Vistagen Therapeutics, Inc.'s VTGN:BMV listing on BMV in MXN for MX, including stock price context, company news, filings, investor events, AI research briefs, and market updates for investors following VTGN:BMV. VTGN:BMV is the stock-level entry point for investors researching Vistagen Therapeutics, Inc., while company-level investor report content can remain shared across the same issuer's public listings. 6ix connects this selected listing to available company updates, filings, investor events, replay content, and AI research briefs so stock search leads to the relevant company context without making another exchange listing primary. Vistagen Therapeutics, Inc. is a public company traded under the ticker VTGN in the American market. The company has a market capitalization of approximately $9.4 million. Vistagen focuses on developing therapies for central nervous system disorders.

Research Vistagen Therapeutics, Inc.

Alternate listings